Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 10/20 | 1.00 |
| ▸ | GRM7 | Q14831 | 10/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 9/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 9/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 6/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 6/20 | 1.00 |
| ▸ | GRM5 | P41594 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079684 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL15060588 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL12019053 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL13746359 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL8490722 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL29389814 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL24606222 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL481153 | 1.00 | GRM8 (1.00) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL7386669 | 0.84 | GRM8 (0.72) | GRM8GRM7GRM2GRM4GRM3 | |
| SCHEMBL7393500 | 0.84 | GRM8 (0.72) | GRM8GRM7GRM2GRM4GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| EP-1817300-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057860-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | GRM8 4497/4885GRM7 3919/4885GRM2 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.